Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
about
Cyclin-dependent kinase inhibitor therapy for hematologic malignanciesChronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted AgentsPotential of plant-derived natural products in the treatment of leukemia and lymphomaTargeting MET transcription as a therapeutic strategy in multiple myeloma.Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules.Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response.Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosisTargeting cell cycle regulators in hematologic malignancies.Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies.Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemiaRelationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis.Histone deacetylase inhibitors: clinical implications for hematological malignancies.Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.Novel treatment strategies for aggressive non-Hodgkin's lymphoma.Update on risk-stratified management for chronic lymphocytic leukemia.Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule.Emerging therapy for chronic lymphocytic leukaemia.Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemiaPhase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapyEmerging drug profile: cyclin-dependent kinase inhibitorsTreatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy.A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk diseaseHLBT-100: a highly potent anti-cancer flavanone from Tillandsia recurvata (L.) LNew angles of attack in the fight against chronic lymphocytic leukemia: the advent of novel non-chemotherapeutic agents.Refractory chronic lymphocytic leukemia--new therapeutic strategies.Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies.A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabineAlvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia.Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients.Inhibitors of cyclin-dependent kinases as cancer therapeutics.A novel liposomal formulation of flavopiridol.Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma.CDK4/6 blockade in breast cancer: current experience and future perspectives.
P2860
Q24561485-F7839719-1BFA-47A2-9898-32AECFBD7F16Q26764833-1B9D49EA-6EBD-49C2-8E5A-CAD6854CB5BFQ33942845-D10ABBBC-A2A5-4664-8E3D-6E2B2421CD71Q33943962-87386835-68E8-4CD7-9ECA-D3F574536452Q33952759-BE0791D3-D904-4262-8722-63ECCE149C80Q34195072-A52E88C1-BAF8-4C8F-A023-EC2F5B8095E1Q34458745-1846B426-2DB3-46EF-AFD6-82719102636CQ34754350-BB8129B2-FF04-4527-B638-FBC0F1D8557FQ35182162-011A9D91-C3EC-42E0-8633-CABB17A5C090Q35214727-0BF9C4A1-04AC-438A-9E48-66BAC3D60066Q35334436-5BEA5F73-E1AF-4608-887A-4FD5D02C3BAAQ35400933-A208D76C-5892-4DB5-B5D6-6F7B395DEA10Q35615823-5D77254F-1229-46BF-AA44-66AFAD25C346Q35714606-34A13AFD-7117-4988-84CA-3E0DA9EB2BCFQ36001847-01887242-E505-4128-9EE3-BCEA8E13E3ABQ36003724-5F94A1CB-9C17-4A59-BD65-868EC4B9DB88Q36363971-2E0AF558-6777-436D-AD6E-27E9780EA510Q36366636-3729C46F-FE11-4DA8-B338-4B48335FC694Q36429727-752A7CED-A9C5-4818-B5CA-D9F72B8CA263Q36634599-902AFBD4-896A-4B28-8271-EE63DEEBDB95Q36825077-BC1547A9-4285-45A0-B604-7FCD829025F7Q36981738-A97B63B4-8C34-4274-B17B-7B6CE4D2FD75Q37142145-EF81FE69-651E-4DE9-8C9A-B68ABF380193Q37163806-A9E5BEA2-A9DC-499C-9325-0352C1085FBAQ37168430-DFD4B00D-F574-45A2-800C-1F3716DFCC5DQ37185372-D7401168-497A-4EB7-92CE-CC00B603B1A7Q37318762-B2A8013A-F9B4-428D-ABE4-AF303AAB4728Q37354482-F2B7B0B9-5174-4D24-ACE3-41AC4C0028A2Q37474415-19EE40A9-39C0-4AB6-BA7D-1734558A6B37Q37686023-05CFE390-5196-4437-93FE-1DE9494217EDQ37767703-B47F5A95-DA76-407F-8DFB-A0EC4B15470DQ37840932-F32A4BF3-A1DA-4043-B0D0-589052A3210BQ37842484-3AA7BB0D-E57D-4118-9D6E-B3CE8D4EBE0BQ38457498-0D90CA69-4204-4110-8EBC-998CE7E65011Q38783064-2DD144D9-FDCB-4371-934C-8C759CA877EBQ38973410-CA52BC0D-BE17-4AAE-966E-EF586E0101AAQ39125016-2A484514-B4C9-487F-AEFC-10FBA002EB6EQ41900653-8E405B2C-1BF0-484E-84B0-30B612F507FAQ47119688-B6B0D097-CD82-4929-8F5F-C67C2143CF6FQ47658848-9017E244-25F3-45C4-8596-6644CF23B7D5
P2860
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Treatment of relapsed chronic ...... Leukemia Group B study 19805.
@ast
Treatment of relapsed chronic ...... Leukemia Group B study 19805.
@en
type
label
Treatment of relapsed chronic ...... Leukemia Group B study 19805.
@ast
Treatment of relapsed chronic ...... Leukemia Group B study 19805.
@en
prefLabel
Treatment of relapsed chronic ...... Leukemia Group B study 19805.
@ast
Treatment of relapsed chronic ...... Leukemia Group B study 19805.
@en
P2093
P50
P1476
Treatment of relapsed chronic ...... Leukemia Group B study 19805.
@en
P2093
Bercedis L Peterson
Janice Gabrilove
Michael R Grever
Olatoyosi M Odenike
P304
P356
10.1158/1078-0432.CCR-04-2276
P407
P577
2005-06-01T00:00:00Z